Thu, 15 Feb 2024 19:23:52 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png 32 32 https://www.oncologynurseadvisor.com/howtotreat/relapse-refractory-multiple-myeloma-bcma-car-t-cell-idecabtagene-vicleucel-ciltacabtagene-autoleucel/ Fri, 01 Mar 2024 10:00:00 +0000 https://www.oncologynurseadvisor.com/?post_type=howtotreat&p=116750 Multiple myeloma (MM) is a blood-related malignancy resulting from the abnormal accumulation of plasma cells. This article discusses the most recent advances in B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory MM. ]]> https://www.oncologynurseadvisor.com/howtotreat/lung-cancer-nsclc-amivantamab-mobocertinib-egfr-ex20ins/ Fri, 12 Jan 2024 10:00:00 +0000 https://www.oncologynurseadvisor.com/?post_type=cch&p=115892 Non-small cell lung cancer (NSCLC) is characterized by heterogeneity and encompasses various histological subtypes. Exon 20 insertion (ex20ins) mutations of the EGFR gene have been identified as oncogenic drivers in NSCLC. This article discusses approved therapies for the treatment of NSCLC with EGFR ex20ins mutations. ]]> https://www.oncologynurseadvisor.com/howtotreat/ibrutinib-steroid-refractory-chronic-gvhd-graft-host-disease-update/ Fri, 01 Apr 2022 09:00:00 +0000 https://www.oncologynurseadvisor.com/?post_type=howtotreat&p=97928 Graft-vs-host disease is a severe complication of allogeneic hematopoietic cell transplantation. There is no standard of care for steroid-refractory cGVHD, and effective treatment options are limited. This article reviews the current understanding and management of this challenging disease, and highlights newer FDA-approved treatment options.]]>